Hookipa pipeline
WebJan 18, 2024 · HOOKIPA’s pipeline includes wholly-owned investigational arenaviral immunotherapeutics targeting Human Papilloma Virus 16-positive cancers, prostate cancer, KRAS-mutated cancers (including ... WebJan 4, 2024 · HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs.
Hookipa pipeline
Did you know?
Web1 day ago · HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, … WebDec 31, 2024 · Hookipa has an infectious disease/oncology pipeline of six therapeutics. including three in clinical trials including HB-101 for CMV (Phase 2), HB-201 for HPV16+ …
Web2 days ago · HOOKIPA's pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed oncology programs. Web1 day ago · HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, …
WebMar 15, 2024 · HOOKIPA further expanded pipeline and strategic collaborations with the Roche/HB-700 agreement for KRAS-mutated cancers. In October 2024, HOOKIPA … WebJul 12, 2024 · Phase 1/2 trial to be HOOKIPA’s first clinical trial in immuno-oncology. NEW YORK, NY, USA and VIENNA, Austria I July 11, 2024 I HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that …
Web1 day ago · HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen …
WebDec 1, 2024 · In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. … royal tropical institute kitWebOur ambition is prevention and cure. Our universal technology can be used in prophylaxis or therapy. It is based on a patent-protected family of engineered viruses, which naturally … Our Pipeline Immuno-Oncology; Infectious Diseases ... On July 25, 2024, … royal trouble imWebJun 17, 2024 · In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The TheraT ® based lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers. royal truck and trailer dearborn miWeb1 day ago · HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, … royal truck and bus durbanWeb1 day ago · NEW YORK and VIENNA, Austria, April 14, 2024 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, the “Company”), a company developing a … royal truck and trailer gaylordWebA diverse pipeline. HOOKIPA’s most advanced immuno-oncology program is HB-200, an arenavirus-based product candidate that targets the highly antigenic HPV16 E6 and E7 proteins and is currently ... royal truck and trailer detroitWebHOOKIPA Pharma Inc. (NASDAQ: ... Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated … royal trt